Semma Therapeutics IPO

Developer of trans-formative therapies designed to eliminate the use of insulin injections for type 1 diabetes patients. The company's trans-formative therapies is a cell-based therapy for diabetes which traditionally requires the use of an invasive insulin pump or multiple daily insulin injections combining proprietary cells with a state-of-the-art device to provide a replacement for the missing beta cells in a diabetic patient without immunosuppression, enabling doctors to provide a functional cure for patients with diabetes.

Register for Details

For more details on financing and valuation for Semma Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Semma Therapeutics

Forge green plus iconForge green minus icon

What is Semma Therapeutics funding to date?

Semma Therapeutics has raised $158MM.
Forge green plus iconForge green minus icon

When was Semma Therapeutics founded?

Semma Therapeutics was founded in 2014.